Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Low-risk Myelodysplastic Syndromes”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT00451997
What this trial is testing

Gleevec/Low-Dose Ara-C Study for Elderly Patients With AML and Myelodysplastic Syndromes

Who this might be right for
Leukemia, MyeloidMyelodysplastic Syndromes
M.D. Anderson Cancer Center 10
Early research (Phase 1)Study completedNCT02038777
What this trial is testing

PF-04449913 In Japanese Patients With Select Hematologic Malignancies

Who this might be right for
Acute Myeloid Leukemia
Pfizer 48
Post-approval studies (Phase 4)Study completedNCT00117507
What this trial is testing

Study for the Treatment of Transfusional Iron Overload in Myelodysplastic Patients

Who this might be right for
Myelodysplastic SyndromesIron Overload
Novartis Pharmaceuticals 24
Testing effectiveness (Phase 2)Study completedNCT00619099
What this trial is testing

Decitabine Given Subcutaneously to Adults With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)

Who this might be right for
Myelodysplastic Syndrome
Eisai Inc. 67
Testing effectiveness (Phase 2)Study completedNCT00068276
What this trial is testing

Cholecalciferol in Treating Patients With Myelodysplastic Syndrome

Who this might be right for
LeukemiaMyelodysplastic SyndromesMyelodysplastic/Myeloproliferative Neoplasms
Wake Forest University Health Sciences
Testing effectiveness (Phase 2)Looking for participantsNCT05384691
What this trial is testing

Efficacy of Luspatercept in ESA-naive LR-MDS Patients With or Without Ring Sideroblasts Who do Not Require Transfusions

Who this might be right for
Myelodysplastic SyndromesAnemia
University of Leipzig 213
Large-scale testing (Phase 3)Study completedNCT00538850
What this trial is testing

Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain

Who this might be right for
Cancer
INSYS Therapeutics Inc 130
Large-scale testing (Phase 3)Study completedNCT01566695
What this trial is testing

The Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Placebo and Best Supportive Care in Subjects With Red Blood Cell (RBC) Transfusion-Dependent Anemia and Thrombocytopenia Due to International Prognostic Scoring System (IPSS) Low Risk Myelodysplastic Syndrome (MDS)

Who this might be right for
Myelodysplastic Syndrome
Celgene 216
Testing effectiveness (Phase 2)Study completedNCT01718379
What this trial is testing

Lenalidomide in Subject With Low and Intermediate-1 Risk MDS and Without Chromosome 5 Abnormality.

Who this might be right for
Myelodysplastic Syndromes
Groupe Francophone des Myelodysplasies 132
Testing effectiveness (Phase 2)Ended earlyNCT04623996
What this trial is testing

TP-0184 to Treat Anemia in Adults With IPSS-R Low or Intermediate Risk MDS

Who this might be right for
Anemia in Myelodysplastic Syndromes
Sumitomo Pharma America, Inc. 2
Testing effectiveness (Phase 2)Study completedNCT01048034
What this trial is testing

Evaluation of Azacitidine in Transfusion Dependent Patients With Low-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML)

Who this might be right for
Myelodysplastic SyndromeChronic Myelomonocytic Leukemia
Nordic MDS Group 30
Testing effectiveness (Phase 2)Looking for participantsNCT05308264
What this trial is testing

Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS)

Who this might be right for
Low Risk Myelodysplastic Syndromes
Rigel Pharmaceuticals 86
Testing effectiveness (Phase 2)WithdrawnNCT05766514
What this trial is testing

Trial of Cladribine and Low-Dose Cytarabine (LoDAC) Alternating With Decitabine vs. Hypomethylating Agents (HMA) Plus Venetoclax as Frontline Therapy for AML or High-Grade MDS in Patients Unfit for Intensive Induction

Who this might be right for
Acute Myeloid LeukemiaMyelodysplastic Syndromes
University of Florida
Early research (Phase 1)Study completedNCT00916227
What this trial is testing

ARRY-614 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome

Who this might be right for
Myelodysplastic Syndromes
Array Biopharma, now a wholly owned subsidiary of Pfizer 45
Testing effectiveness (Phase 2)Ended earlyNCT05178342
What this trial is testing

Treatment of Anemia in Patients With Very Low, Low or Intermediate Risk Myelodysplastic Syndromes With CA-4948

Who this might be right for
Myelodysplastic SyndromesAnemia
University of Leipzig 38
Large-scale testing (Phase 3)Active Not RecruitingNCT05883956
What this trial is testing

A Study Comparing Treatment Preference Between Oral Decitabine/Cedazuridine and Azacitidine in Myelodysplastic Syndrome, Low-Blast Acute Myeloid Leukemia, or Chronic Myelomonocytic Leukemia

Who this might be right for
Myelodysplastic SyndromesLeukemia, Myeloid, AcuteLeukemia, Myelomonocytic, Chronic+1 more
Otsuka Australia Pharmaceutical Pty Ltd 13
Post-approval studies (Phase 4)Study completedNCT00452660
What this trial is testing

Evaluation the Effect of Exjade on Oxidative Stress in Low Risk Myelodysplastic Syndrome Patients With Iron Over Load

Who this might be right for
Myelodysplastic Syndrome
Wolfson Medical Center 21
Large-scale testing (Phase 3)Ended earlyNCT03263091
What this trial is testing

Efficacy and Safety of Roxadustat for Treatment of Anemia in Participants With Lower Risk Myelodysplastic Syndrome With Low Red Blood Cell Transfusion Burden

Who this might be right for
Primary MDS (Very Low, Low or Intermediate IPSS-R With <5% Blasts)Anemia
Kyntra Bio 184
Testing effectiveness (Phase 2)Ended earlyNCT01034657
What this trial is testing

LBH589 Alone or in Combination With Erythropoietin Stimulating Agents (ESA) in Patients With Low or Int-1 Risk Myelodysplastic Syndromes (MDS)

Who this might be right for
Myelodysplastic Syndrome (MDS)
Novartis Pharmaceuticals 34
Testing effectiveness (Phase 2)Looking for participantsNCT04419649
What this trial is testing

Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS)

Who this might be right for
Myelodysplastic SyndromesCytopenia
Takeda 160
Next Page